Medical Devices China

China Newborn Screening Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

China Newborn Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $81.3 Mn Placeholder estimate
Estimate 2025 $90.1 Mn 7.6% of the global market
Projected 2034 $226.8 Mn 151.7% Adds $136.7 Mn over 9 forecast years
CAGR 2025–2034 10.8% Faster than 54% of 173 Medical Devices markets here
Key players 5
  • China is 7.58% of the global market.
  • In APAC, the largest is China (this report) at $90.1 Mn.
  • Fastest growing: India at 12% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$136.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Newborn Screening Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $81.3 Mn — —
2025 (base) $90.1 Mn +$8.8 Mn —
2026 (forecast) $99.8 Mn +$9.7 Mn +10.8%
2027 (forecast) $110.6 Mn +$10.8 Mn +22.8%
2028 (forecast) $122.6 Mn +$11.9 Mn +36%
2029 (forecast) $135.8 Mn +$13.2 Mn +50.7%
2030 (forecast) $150.5 Mn +$14.7 Mn +67%
2031 (forecast) $166.7 Mn +$16.3 Mn +85%
2032 (forecast) $184.7 Mn +$18.0 Mn +105%
2033 (forecast) $204.7 Mn +$20.0 Mn +127.2%
2034 (forecast) $226.8 Mn +$22.1 Mn +151.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.19 Bn
  2. North America $567.9 Mn
  3. US $459.4 Mn
  4. Europe $219.2 Mn
  5. APAC $219.1 Mn
  6. Canada $102.6 Mn
  7. China (this report) $90.1 Mn
  8. Japan $85.7 Mn
  9. Latin America $58.8 Mn
  10. Middle East $47.7 Mn
  11. Germany $39.8 Mn
  12. UK $31.3 Mn
  13. Brazil $31.6 Mn
  14. Italy $30.5 Mn
  15. France $28.9 Mn
  16. Saudi Arabia $23.7 Mn
  17. Ecuador $22.7 Mn
  18. Spain $20.0 Mn
  19. Africa $20.5 Mn
  20. India $19.9 Mn
  21. Mexico $15.6 Mn
  22. Australia $13.7 Mn
  23. New Zealand $12.6 Mn
  24. Russia $10.8 Mn
  25. South Africa $8.6 Mn
  26. UAE $5.4 Mn
  27. Egypt $3.1 Mn
  28. Philippines $2.5 Mn
  29. Malaysia $2.2 Mn
  30. Hong Kong $1.7 Mn
  31. Singapore $1.6 Mn
  32. Thailand $1.4 Mn
  33. Kenya $0.9 Mn

Report snapshot

China Newborn Screening Market Analysis at a glance
Market size, 2025$90.1 Mn placeholder estimate
Forecast, 2034$226.8 Mn placeholder estimate
Growth (CAGR), 2025–203410.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, technology and end user (see all)
Key playersRevvity, Natus Medical, Trivitron Healthcare, Bio-Rad Laboratories, Masimo Corporation (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Newborn Screening Market Analysis Executive Summary

Newborn screening tests babies shortly after birth for rare but serious conditions such as metabolic, hormone and genetic disorders.

Key segments of the newborn Screening market include test (Dried Blood Spot Tests, Hearing Screening and Pulse Oximetry) and technology (Tandem Mass Spectrometry, Immunoassays and DNA Assays).

Bar chart: China Newborn Screening market size, 2024–2034, placeholder estimates. $81.3 Mn in 2024, $90.1 Mn in 2025 and $226.8 Mn in 2034, 10.8% CAGR.
China Newborn Screening market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Newborn Screening Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the newborn Screening market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the newborn Screening market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the newborn Screening market.

Competitive Landscape for Newborn Screening Market in China

The newborn Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Newborn Screening Market in China

Newborn Screening in China: rules, payment and health figures

Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] Newborn deaths (first 28 days): 2.6 per 1,000 live births in 2024, the latest WHO figure for China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Newborn deaths (first 28 days) (per 1,000 live births). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how newborn Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Newborn Screening right now, from free public sources.

Latest research 3,809 papers since 2021 (worldwide)

  1. Early-onset epilepsy and inborn errors of metabolism: A large retrospective pediatric cohort. Epilepsy & behavior : E&B, 2026
  2. [Newborn screening in Spain: equity, clinical value and challenges in the context of technological expansion]. Revista espanola de salud publica, 2026
  3. Regional newborn screening for Gaucher disease in Kumamoto and Fukuoka Prefectures, Japan: an updated report and long-term outcomes of screen-identified patients. Molecular genetics and metabolism, 2026
  4. Newborn Screening for Duchenne Muscular Dystrophy: Contemporary Considerations for Implementation of an Early Diagnostic Paradigm. Neurology, 2026
  5. Cystic fibrosis: remarkable success but still not at the finish line. Proceedings (Baylor University. Medical Center), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Newborn Screening in context

China compared

  • Newborn deaths (first 28 days): 2.6 per 1,000 live births (2024). World: 17.2 per 1,000 live births (2024). 12th highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[3]

[1] World Bank Open Data, Newborn deaths (first 28 days) (per 1,000 live births). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Newborn Screening market in China?
Placeholder estimate: about $90.1 Mn in 2025, rising to about $226.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Newborn Screening market in China growing?
Placeholder estimate: about 10.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Newborn Screening market report cover?
The report splits the market by test (Dried Blood Spot Tests, Hearing Screening, Pulse Oximetry, Genomic Screening), technology (Tandem Mass Spectrometry, Immunoassays, DNA Assays) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Newborn Screening market?
Key players include Revvity, Natus Medical, Trivitron Healthcare, Bio-Rad Laboratories and Masimo Corporation.
What is driving the Newborn Screening market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the newborn Screening market.
Who regulates Newborn Screening in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
What does WHO report for China?
Newborn deaths (first 28 days): 2.6 per 1,000 live births in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Newborn deaths (first 28 days) (per 1,000 live births). Retrieved 15 Nov 2026.
How many people in China are 65 or older?
14.9% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
How much research is published on Newborn Screening?
PubMed lists 3,809 papers on Newborn Screening added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Newborn Screening in China? Our analysts can size it for your plan. Talk to us See the public data Newborn deaths (first 28 days) for every country, free. Open the Public Health Dashboard

From our blog

Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
Back to Catalogue
Keep exploring

Related Medical Devices reports in China

See all
Same topic, other categories

Related on diagnostics and lab testing and neonatal

See the topic